Trial Profile
A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of DA-9805 in Subjects With Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 May 2022
Price :
$35
*
At a glance
- Drugs DA 9805 (Primary)
- Indications Parkinson's disease
- Focus First in man; Therapeutic Use
- Sponsors Dong-A ST
- 07 Feb 2020 Status changed from active, no longer recruiting to completed.
- 01 Jan 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Mar 2019.
- 01 Jan 2019 Status changed from recruiting to active, no longer recruiting.